Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Apt interpretation of comprehensive lipoprotein data in large-scale epidemiology – disclosure of fundamental structural and metabolic relationships

View ORCID ProfileMika Ala-Korpela, Siyu Zhao, Marjo-Riitta Järvelin, Ville-Petteri Mäkinen, Pauli Ohukainen
doi: https://doi.org/10.1101/2021.03.08.21253123
Mika Ala-Korpela
1Computational Medicine, Faculty of Medicine, University of Oulu, Oulu, Finland
2Center for Life Course Health Research, Faculty of Medicine, University of Oulu, Oulu, Finland
3Biocenter Oulu, University of Oulu, Oulu, Finland
4NMR Metabolomics Laboratory, School of Pharmacy, University of Eastern Finland, Kuopio, Finland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Mika Ala-Korpela
  • For correspondence: mika.ala-korpela@oulu.fi
Siyu Zhao
1Computational Medicine, Faculty of Medicine, University of Oulu, Oulu, Finland
2Center for Life Course Health Research, Faculty of Medicine, University of Oulu, Oulu, Finland
3Biocenter Oulu, University of Oulu, Oulu, Finland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marjo-Riitta Järvelin
2Center for Life Course Health Research, Faculty of Medicine, University of Oulu, Oulu, Finland
3Biocenter Oulu, University of Oulu, Oulu, Finland
5Unit of Primary Health Care, Oulu University Hospital, OYS, Oulu, Finland
6Department of Epidemiology and Biostatistics, MRC-PHE Centre for Environment and Health, School of Public Health, Imperial College London, London, UK
7Department of Life Sciences, College of Health and Life Sciences, Brunel University London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ville-Petteri Mäkinen
8Australian Centre for Precision Health, University of South Australia, Adelaide, Australia
9Computational and Systems Biology Program, Precision Medicine Theme, South Australian Health and Medical Research Institute, Adelaide, Australia.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pauli Ohukainen
1Computational Medicine, Faculty of Medicine, University of Oulu, Oulu, Finland
2Center for Life Course Health Research, Faculty of Medicine, University of Oulu, Oulu, Finland
3Biocenter Oulu, University of Oulu, Oulu, Finland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Aims Quantitative lipoprotein analytics by NMR spectroscopy is currently commonplace in large-scale studies. One methodology has become widespread and is currently being utilised also in large biobanks. It allows comprehensive characterisation of 14 lipoprotein subclasses, clinical lipids, apolipoprotein A-I and B. The details of these data are conceptualised here in relation to lipoprotein metabolism with particular attention to the fundamental characteristics of subclass particle numbers, lipid concentrations and compositional measures.

Methods and Results The NMR methodology was applied to fasting serum samples from Northern Finland Birth Cohort 1966 and 1986 with 5,651 and 5,605 participants, respectively. All results were highly coherent between the cohorts. Circulating lipid concentrations in a particular lipoprotein subclass arise predominantly as the result of the circulating number of those subclass particles. The spherical lipoprotein particle shape, with a radially oriented surface monolayer, imposes size-dependent biophysical constraints for the lipid composition of individual subclass particles and inherently restricts the accommodation of metabolic changes via compositional modifications. The new finding that the relationship between lipoprotein subclass particle concentrations and the particle size is log-linear reveal that circulating lipoprotein particles are also under rather strict metabolic constraints for both their absolute and relative concentrations.

Conclusion The fundamental structural and metabolic relationships between lipoprotein subclasses elucidated in this study empower detailed interpretation of lipoprotein metabolism. Understanding the intricate details of these extensive data is consequential for the precise interpretation of novel therapeutic opportunities and for fully utilising the potential of forthcoming analyses of genetic and metabolic data in extensive biobanks.

One-sentence Summary NMR spectroscopy facilitates comprehensive characterisation of lipoprotein subclass metabolism and offers additional value to epidemiology, genetics and pharmacology in large-scale studies and biobanks.

Key Messages

  • The circulating particle number of a lipoprotein subclass is the defining measure for its lipid concentrations; the particle lipid composition is only in a minor role. The relationship between circulating lipoprotein subclass particle concentrations and the particle size is log-linear.

  • The overall structure of lipoprotein subclass particles with a spherical shape and an oriented surface monolayer poses strong size-dependent biomolecular constraints for their lipid composition.

  • The circulating lipoprotein subclass particle concentrations in humans are metabolically constraint for both elemental absolute and relative concentration ranges.

  • The smallest HDL particle concentrations are negatively associated with those of large HDL and generally the associations of the smallest HDL particles are similar to those of apolipoprotein B-containing particles.

  • The apolipoprotein B-containing particles constitute less than 10% of all lipoprotein particles but carry around two thirds of circulating lipoprotein lipids. LDL and IDL particles amount to almost 90% of all apolipoprotein B-containing particles.

  • The supplemental role of lipoprotein subclass data in cardiometabolic risk assessment is slight.

  • In the current era of biobanks and big data, the combination of lipoprotein subclass data with drug-target Mendelian randomization analyses provides great scientific synergy, intricate details and potential cost savings in drug development.

Figure
  • Download figure
  • Open in new tab

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

MAK is supported by a research grant from the Sigrid Juselius Foundation, Finland. PO is supported by the Emil Aaltonen Foundation. The Northern Finland Birth Cohorts have received funding from the Academy of Finland, Novo Nordisk Foundation, and EU.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The studies comply with the Declaration of Helsinki, were approved by the local ethics committee (Northern Ostrobothnia Hospital District, Finland) and written informed consents were obtained from each participant.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

The datasets used in the current study are available from the cohorts through application process for researchers who meet the criteria for access to confidential data: https://www.oulu.fi/nfbc/.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted March 08, 2021.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Apt interpretation of comprehensive lipoprotein data in large-scale epidemiology – disclosure of fundamental structural and metabolic relationships
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Apt interpretation of comprehensive lipoprotein data in large-scale epidemiology – disclosure of fundamental structural and metabolic relationships
Mika Ala-Korpela, Siyu Zhao, Marjo-Riitta Järvelin, Ville-Petteri Mäkinen, Pauli Ohukainen
medRxiv 2021.03.08.21253123; doi: https://doi.org/10.1101/2021.03.08.21253123
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Apt interpretation of comprehensive lipoprotein data in large-scale epidemiology – disclosure of fundamental structural and metabolic relationships
Mika Ala-Korpela, Siyu Zhao, Marjo-Riitta Järvelin, Ville-Petteri Mäkinen, Pauli Ohukainen
medRxiv 2021.03.08.21253123; doi: https://doi.org/10.1101/2021.03.08.21253123

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Epidemiology
Subject Areas
All Articles
  • Addiction Medicine (162)
  • Allergy and Immunology (416)
  • Anesthesia (91)
  • Cardiovascular Medicine (863)
  • Dentistry and Oral Medicine (159)
  • Dermatology (98)
  • Emergency Medicine (251)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (394)
  • Epidemiology (8573)
  • Forensic Medicine (4)
  • Gastroenterology (388)
  • Genetic and Genomic Medicine (1759)
  • Geriatric Medicine (167)
  • Health Economics (373)
  • Health Informatics (1250)
  • Health Policy (622)
  • Health Systems and Quality Improvement (469)
  • Hematology (196)
  • HIV/AIDS (378)
  • Infectious Diseases (except HIV/AIDS) (10319)
  • Intensive Care and Critical Care Medicine (553)
  • Medical Education (192)
  • Medical Ethics (51)
  • Nephrology (213)
  • Neurology (1682)
  • Nursing (97)
  • Nutrition (252)
  • Obstetrics and Gynecology (328)
  • Occupational and Environmental Health (451)
  • Oncology (930)
  • Ophthalmology (264)
  • Orthopedics (102)
  • Otolaryngology (172)
  • Pain Medicine (114)
  • Palliative Medicine (40)
  • Pathology (254)
  • Pediatrics (538)
  • Pharmacology and Therapeutics (254)
  • Primary Care Research (209)
  • Psychiatry and Clinical Psychology (1775)
  • Public and Global Health (3854)
  • Radiology and Imaging (626)
  • Rehabilitation Medicine and Physical Therapy (320)
  • Respiratory Medicine (521)
  • Rheumatology (208)
  • Sexual and Reproductive Health (168)
  • Sports Medicine (158)
  • Surgery (191)
  • Toxicology (36)
  • Transplantation (101)
  • Urology (76)